Search

Due to the nano-photocatalysts are difficult to recycle in application, TiO2/melamine sponge monolith (TM) photocatalysts composite were successfully prepared by hydrothermal method using melamine sponge (MS) as the carrier and framework. The TMs were characterized by XRD, FT-IR, SEM, UV-Vis DRS and other analytical methods. The effect of hydrothermal time on the photocatalytic performance of TM was studied. The results show that the TM has integrated structure and TiO2 is firmly attached when the hydrothermal time is 16 h. The degradation rate of methylene blue (MB) after 120 min irriadiation reaches 99.3%. TM has a high stability of repeated use. The effective combination of TiO2 and MS enhances the dispersion and light utilization rate of TiO2, thereby improving the photocatalytic performance of TM and facilitating recycling.

Copyright of Journal of Xi'an Polytechnic University is the property of Editorial Department of Journal of Xi'an Polytechnic University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Fuzhou University is the property of Journal of Fuzhou University, Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Dalian University of Technology / Dalian Ligong Daxue Xuebao is the property of Journal of Dalian University of Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The main component of the Center for Genetic Engineering and Biotechnology (CIGB) candidate vaccine against Hepatitis C virus (HCV) is the pIDKE2 plasmid.The current designed downstream process for the production of pIDKE2 fulfils all regulatory requirements and renders the required quantities of pharmaceutical-grade plasmid DNA (pDNA) with 95% purity.The advantages of this procedure include high plasmid purity and the elimination of undesirable additives,such as toxic organic extractants and animal-derived enzymes.However,yields and consequently the productivity of the process are low.Previous work demonstrated that the most critical step of the process is the reverse phase chromatography,where conventional porous particle resins are used.Therefore,to increase the process productivity,alternative technologies such as membranes and chromatographic monoliths were tested as alternative options for this critical step.Here,a comparison between the behaviors of CIM ® C4-HLD and Sartobind phenyl matrices was performed.To obtain higher productivities and purities,the dynamic binding capacities and selectivities were evaluated.The results showed that both matrices had a similar capacity for pIDKE2 plasmid,but the separation of pDNA isoforms using CIM technology was much better than that with Sartobind.Additionally,the optimal conditions for loading plasmid DNA on a CIM ® C4-HLD 800-mL monolithic column in a real production process were determined.These optimizations will allow production levels to satisfy the high plasmid consumption demanded by clinical trials.